# A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

> **NCT01089010** · PHASE2 · COMPLETED · sponsor: **Cytokinetics** · enrollment: 67 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** Placebo
- **DRUG:** 250 mg CK-2017357
- **DRUG:** 500 mg CK-2017357

## Key facts

- **NCT ID:** NCT01089010
- **Lead sponsor:** Cytokinetics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2019-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01089010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01089010, "A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01089010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*